Translating Molecular Determinants Of Susceptibility And Progression In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$6,510,085.00
Summary
Breast cancer is the most common cancer in women. Despite improvements in prevention, detection and treatment, it is the 2nd most common cause of cancer death in Australian women. Research advances in the last decade have improved our understanding of the pathways from susceptibility to progression and metastasis but this has mostly not yet translated into better outcomes. This program aims to translate some of our fundamental discoveries to improve outcome for affected women and their families.
Generating The Evidence To Control Cancer And Optimise Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$6,564,341.00
Summary
Our Program addresses the public health aspects of common cancers, particularly cancers of the skin and gynaecological tracts. Each year in Australia, nearly 400,000 people are treated for skin cancer, and more than 3,500 women develop ovarian or uterine cancer. Our aims are first, to understand how we might prevent these cancers in the future; second, to enhance diagnosis of these cancers; and third, to improve the survival and quality of life for people who are diagnosed with these cancers
Optimising Heart Disease Prevention And Management
Funder
National Health and Medical Research Council
Funding Amount
$4,647,175.00
Summary
As we become older and risk factors such as obesity become more common, our biggest contributor to death and disability, cardiovascular disease (including heart disease), will continue to exert an enormous burden on our health care system and society. We will extend our ground-breaking research on multidisciplinary teams to create new and innovative health care programs to optimise the prevention and management of new heart disease and chronic forms of heart disease.
Precision Nanomedicine-based Diagnostics And Therapeutics For Refractory Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$7,329,484.00
Summary
The vast majority of cancer patients die of their disease due to the emergence of drug resistant cancer cells or metastatic disease that is diagnosed at late stages. Our program aims to develop new types of therapy to specifically target aggressive cancers. To detect cancer early and evaluate the effectiveness of cancer therapy, we will develop sensitive diagnostic tools and devices. This research has application to both childhood and adult cancers.
We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells. We wish to learn how cancer can sometimes evade the immune system. Our work will also find out how some common treatments for cancer, like chemotherapy, can be used to boost the immune system and eliminate tumours. Through knowledge gained from these studies, we aim to develop new therapies that can help patients with devastating diseases like cancer.
This Program team will discover new things about immunity to cancer and virus infection and translate the information into novel therapies in patients with blood or solid cancers. The approaches will include new cellular or antibody therapies, alone or in combination. We will determine new predictive biomarkers to better select patients for therapy. We will overcome treatment resistance, improve the safety of combination therapies, and determine their best scheduling and dosing.
Drug-related deaths in Australia account for 6.6% of all deaths (ABS 2009). In much of the rural Asia-Pacific, pesticide poisoning and snakebite are major problems. We propose an integrated and international human toxicology research program covering medicine and chemical poisoning, serious adverse drug reactions, snake and spider bite. Our focus is on the applied research needed to detect new problems and rapidly translate early findings into better treatment, regulations & policy.
At least 6 young Australians are diagnosed each day with type 1 diabetes. This Program aims to change the way type 1 diabetes is managed by proactively treating its underlying mechanisms. We will develop safer and more effective immune therapies, develop islet transplantation, look for better markers of disease, and identify ways to preserve insulin-producing cells. The Program aims to propel type 1 diabetes research forward to reach the goals of prevention and cure.
Linking Lifestyle And Molecular Biology To Inform Precision Public Health For Major Cancers
Funder
National Health and Medical Research Council
Funding Amount
$8,487,111.00
Summary
The Program of research seeks to increase our understanding of cancer risk. We will use our large collections of population and family-based datasets to conduct innovative analyses, improving our understanding of the roles that genetic, epigenetic and lifestyle factors play in our risk of breast, colorectal and prostate cancer. This information should allow us to better predict a person’s cancer risk, enabling public health interventions, such as screening, to be delivered more effectively and e ....The Program of research seeks to increase our understanding of cancer risk. We will use our large collections of population and family-based datasets to conduct innovative analyses, improving our understanding of the roles that genetic, epigenetic and lifestyle factors play in our risk of breast, colorectal and prostate cancer. This information should allow us to better predict a person’s cancer risk, enabling public health interventions, such as screening, to be delivered more effectively and economically to those most at risk.Read moreRead less
Stroke outcomes directly relate to brain tissue rescue. We have contributed to changes in clinical practice through many clinical trials of new protocols and therapeutic strategies. Our program will focus on brain salvage in the pre-hospital setting and the acute hospital environment. We will use novel approaches to enhance brain recovery and design new implementation strategies to maximise the benefits of these therapeutic advances.